1) 日本更年期医学会編 : 更年期医療ガイドブック.金原出版,2008年
2) Hertig AT : Landmark perspective. Allen and Doisy's 'An ovarian hormone'. JAMA 250 : 2684─2688, 1983
3) Allen E, Doisy EA : Landmark article Sept 8, 1923. An ovarian hormone. preliminary report on its localization, extraction and partial purification, and action in test animals. JAMA 250 : 2681─2683, 1983
4) Ziel HK, Finkle WD : Increased risk of endometrial carcinoma among users of conjugated estrogens. New Engl J Med 293 : 1167─1170, 1975
5) Gambrell RD Jr, Massey FM, Castaneda TA, et al : Use of the progestogen challenge test to reduce the risk of endometrial cancer.Obstet Gynecol 55 : 732─738, 1980
6) Thigpen JT, Brady MF, Alvarez RD, et al : Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma : a dose─response study by the gynecologic oncology group. J Clin Oncol 17 : 1736─1744, 1999
7) Nachtigall LE, Nachtigall RH, Nachtigall RD, et al : Estrogen replacement therapy I : a 10─years prospective study in the relationship to osteoporosis.Obstet Gynecol 53 : 277─281, 1979
8) Genant HK, Cann CE, Ettinger B, et al : Quantitative computed tomograpy of vertebral spongiosa : a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97 : 699─705, 1982
9) Wilbush J : La ménespausie─the birth of a syndorome.Maturitas 1 : 145─151, 1979
10) The writing group for the PEPI : Effects of hormone therapy on bone mineral density : results from the postmenopausal estrogen/progestin interventions(PEPI)trial. JAMA 276 : 1389─1396, 1996
11) Collaborative group on hormonal factors in breast cancer : Breast cancer and hormone replacement therapy : collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350 : 1047─1059, 1997
12) Persson I, Thurfjell E, Bergström R, et al : Hormone replacement therapy and the risk of breast cancer, nested case─control study in a cohort of Swedish women attending mammography screening. Int J Cancer 72 : 758─761, 1997
13) Women's Health Initiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 : 321─333, 2002
14) 久具宏司,矢野 哲,武谷雄二 : WHTを考慮したHRTの適応とインフォームド・コンセント.臨婦産57 : 777─781,2003
15) Women's Health Initiative steering committee : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women's Health Initiative randomized controlled trial.JAMA 291 : 1701─1712, 2004
16) Women's Health Initiative Investigators : Conjugated equine estrogens and coronary heart disease : the Women's Health Initiative.Arch Intern Med 166 : 357─365, 2006
17) Salpeter SR, Walsh JM, Greyber E, et al : Brief reportCoronary heart disease events associated with hormone therapy in younger and older women. A meta─analysis. J Gen Intern Med 21 : 363─366, 2006
18) Million Women Study Collaborators : Breast cancer and hormone─replacement therapy in the Million Women Study. Lancet 362 : 419─427, 2003
19) Archer DF, Dorin M, Lewis V, et al : Effects of lower doses of conjugated equine estrogens and medoroxyprogesterone acetate on endometrial bleeding. Fertil Steril 75 : 1080─1087, 2001
20) 若槻明彦 : 心血管疾患の発症予防を目的とした新しいホルモン補充療法の開発.日産婦誌57 : 1836─1843,2005
21) 「WHI中間報告」に対する見解と,現時点での本邦におけるHRTのあり方.日更年医会誌12 : 110─112,2004
22) 大石 元,久具宏司,矢野 哲,他 : WHIのどの点が見直されているのか.HORM FROT GYNECOL 15 : 191─196,2008
23) Pines A, Sturdee DW, Birkhäuser MH, et al : Board of the international menopause society : IMS updated recommendations on postmenopausal hormone therapy. Climacteric 10 : 181─194, 2007